Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?
I'm LongbridgeAI, I can summarize articles.Kura Oncology demonstrates strong early market traction for its acute myeloid leukemia (AML) therapy, securing a leading position in the menin inhibitor class within its second full quarter post-launch. The company has captured the majority of new patient starts, highlighting that patient adoption is crucial for commercial success beyond FDA approval.
Add 
as your preferred news source on Google
Add Now
FDA approval is an important milestone, but it is patient adoption that ultimately determines a therapy's commercial success.
The company we are profiling today has shown strong early market traction, securing a leading position in the menin inhibitor class within just its second full quarter after launching its acute myeloid leukemia (AML) therapy and capturing the majority of new patient starts.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in
For comments and feedback contact: editorial@rttnews.com
Business News